Brokerages Set Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Target Price at $181.71

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $181.64.

Several analysts have recently weighed in on the company. Royal Bank Of Canada lowered their target price on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Needham & Company LLC reaffirmed a "buy" rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, June 11th. Morgan Stanley decreased their price target on shares of Jazz Pharmaceuticals from $166.00 to $165.00 and set an "overweight" rating on the stock in a research report on Tuesday. Wall Street Zen downgraded Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Jazz Pharmaceuticals in a report on Tuesday, July 15th. They set a "buy" rating and a $152.00 price target on the stock.

Jazz Pharmaceuticals Stock Up 0.2%

NASDAQ JAZZ traded up $0.22 during trading hours on Tuesday, hitting $118.23. The company had a trading volume of 549,702 shares, compared to its average volume of 632,451. Jazz Pharmaceuticals has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The company has a market capitalization of $7.15 billion, a price-to-earnings ratio of 15.76, a P/E/G ratio of 5.68 and a beta of 0.32. The company has a debt-to-equity ratio of 1.28, a current ratio of 3.38 and a quick ratio of 2.97. The firm's 50 day moving average is $110.22 and its 200 day moving average is $118.07.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The company had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. During the same quarter in the prior year, the company posted $2.68 earnings per share. The firm's revenue for the quarter was down .5% on a year-over-year basis. Sell-side analysts anticipate that Jazz Pharmaceuticals will post 16.96 earnings per share for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the company's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $116.35, for a total transaction of $116,350.00. Following the completion of the transaction, the chief executive officer owned 439,307 shares of the company's stock, valued at approximately $51,113,369.45. This represents a 0.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Seamus Mulligan acquired 100,000 shares of the business's stock in a transaction dated Friday, May 9th. The shares were bought at an average cost of $98.26 per share, with a total value of $9,826,000.00. Following the transaction, the director directly owned 100,000 shares of the company's stock, valued at $9,826,000. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have sold 2,500 shares of company stock valued at $277,930 in the last ninety days. 4.30% of the stock is owned by company insiders.

Institutional Trading of Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in JAZZ. HighTower Advisors LLC increased its stake in Jazz Pharmaceuticals by 27.0% in the fourth quarter. HighTower Advisors LLC now owns 9,648 shares of the specialty pharmaceutical company's stock valued at $1,188,000 after acquiring an additional 2,054 shares during the period. Avantax Advisory Services Inc. bought a new stake in Jazz Pharmaceuticals in the fourth quarter valued at about $264,000. Envestnet Portfolio Solutions Inc. increased its stake in Jazz Pharmaceuticals by 19.0% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 3,146 shares of the specialty pharmaceutical company's stock valued at $387,000 after acquiring an additional 502 shares during the period. Corient Private Wealth LLC increased its stake in Jazz Pharmaceuticals by 34.5% in the fourth quarter. Corient Private Wealth LLC now owns 10,857 shares of the specialty pharmaceutical company's stock valued at $1,335,000 after acquiring an additional 2,784 shares during the period. Finally, Xponance Inc. increased its stake in Jazz Pharmaceuticals by 17.7% in the fourth quarter. Xponance Inc. now owns 7,946 shares of the specialty pharmaceutical company's stock valued at $979,000 after acquiring an additional 1,195 shares during the period. Institutional investors own 89.14% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.